BAYER AG

2024 mirrors 2023 in biotech, with middle-market companies in survival mode. A post-pandemic hangover persists, marked by a 'haves and have-nots' dynamic favoring later-stage assets. Biopharma raised $20.8B in 2024 vs. $54.1B in 2021, with layoffs and IPO struggles. Uncertainty under the new administration impacts the industry, but M&A activity is picking up.

The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.

The 2025 Therapeutics Market Report highlights the dynamic growth driven by R&D in oncology, neurology, and immunology, focusing on trends like cancer immunotherapy, regenerative medicine, and digital therapeutics. It profiles leading companies and startups, emphasizing the role of funding and collaboration in advancing therapeutics. The report serves as a guide for stakeholders, investors, and policymakers, providing insights into market growth and innovation.

The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.

Animal Biotechnology integrates biological sciences and technologies to improve livestock management, disease control, and animal health, addressing global challenges like food security and climate change. The market is set for growth, driven by technological advancements in genomics and rising consumer demand for high-quality animal products. Key players include Bayer AG, Pfizer, Inc., Sanofi, and others, with opportunities for new entrants in precision breeding and vaccines. STATS N DATA's report offers insights into market trends, growth drivers, and regional analysis to 2031.

The module discusses precision oncology, emphasizing integrated healthcare solutions, genomics testing, and next-generation sequencing (NGS) recommendations for solid tumours. It highlights the importance of structured genomics reports and the transformative impact of clinical trials. The author also explores socio-economic and ethical implications of molecularly-guided treatment options, advocating for multi-stakeholder collaboration.

The Global AI in Biotechnology Market is projected to grow from US$ 4.5 Billion in 2023 to US$ 26.3 Billion by 2033, driven by precision medicine, drug discovery, and personalized healthcare. North America leads with a 40.8% share, and AI technologies like machine learning and natural language processing are transforming biotechnology. Key applications include drug target identification and agriculture biotechnology, with software leading in product types. Partnerships and collaborations are accelerating AI integration in biotechnology.

Aignostics raises $34 million in Series B funding to support new product offerings, US expansion, and pathology foundation model development with Mayo Clinic.

The article discusses the shift in clinical research from inclusive to extractive, influenced by outsourcing to CROs and centralization of decision-making, leading to challenges in patient recruitment and site support. It suggests solutions like increased site support, forming strong country teams, engaging investigators in management practices, and improving payment processes to make clinical research more inclusive and effective.

The ARANOTE trial demonstrated that darolutamide plus androgen-deprivation therapy (ADT) without chemotherapy improved radiological progression-free survival by 46% in metastatic hormone-sensitive prostate cancer (mHSPC) patients compared to placebo plus ADT (HR 0.54, 95% CI 0.41-0.71, P<0.0001). The combination showed consistent benefits across subgroups, including high- and low-volume disease, and improved overall survival (OS) rates at 24 months (79.8% vs. 75.5%). Darolutamide also exhibited better tolerability with lower rates of fatigue and adverse event-related discontinuation compared to placebo.